NeuroEM Therapeutics develops wearable neuromodulation devices designed to deliver transcranial electromagnetic treatment (TEMT) for neurodegenerative disease. The company’s technology uses electromagnetic fields applied non-invasively through a head-worn device. Its approach aims to influence brain processes associated with Alzheimer’s disease and related dementias without surgical intervention. NeuroEM Therapeutics positions its platform within regulated therapeutic development contexts.

The technology delivers low-level electromagnetic signals to the brain through a wearable headset. These signals are designed to penetrate brain tissue and interact with biological processes implicated in neurodegeneration. Treatment protocols are intended for repeated use, supporting ongoing modulation rather than one-time intervention. The system does not rely on neural recording, focusing instead on therapeutic field delivery.

NeuroEM Therapeutics targets patients with Alzheimer’s disease and related dementias who may benefit from non-pharmacological treatment approaches. The platform is intended for use within clinical research and therapeutic evaluation pathways rather than consumer wellness. Its positioning reflects broader interest in electromagnetic neuromodulation as a potential tool for addressing neurodegenerative disorders.